Literature DB >> 10825039

Clinical reactogenicity of intradermal bacille Calmette-Guérin vaccination.

D F Hoft1, C Leonardi, T Milligan, G T Nahass, B Kemp, S Cook, J Tennant, M Carey.   

Abstract

Clinical, microbiological, and immunologic responses were evaluated in volunteers vaccinated intradermally with bacille Calmette-Guérin (BCG). Most volunteers (98%) developed ulcerative lesions that drained for a mean +/- SE of 4.3 +/- 0.29 weeks. Mycobacterial DNA was detected by a polymerase chain reaction-based amplification technique in biopsy specimens from BCG ulcers 2 weeks after vaccination and in blood specimens 3 days after vaccination. Mycobacteria were cultured from ulcer drainage 2 months after vaccination, demonstrating a prolonged potential risk of contact spread of the vaccine strain. The duration of ulcer drainage was inversely correlated with prevaccination lymphoproliferative (r = -0.515; P < .002) and interferon gamma (r = -0.841; P < .002) responses specific to mycobacteria and directly correlated with postvaccination increases in lymphoproliferative (r = 0.498; P < .002) and interferon gamma (r = 0.688; P < .02) responses specific to mycobacteria. These results demonstrate the clinical reactogenicity of BCG and the potential risk of contact spread of the vaccine strain and suggest that clinical reactogenicity is a trade-off for the induction of protective mycobacterial immunity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10825039     DOI: 10.1086/515201

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  TB Vaccines: The (Human) Challenge Ahead.

Authors:  David A Hokey
Journal:  Mycobact Dis       Date:  2014-08

2.  Safety and reactogenicity of BCG revaccination with isoniazid pretreatment in TST positive adults.

Authors:  Mark Hatherill; Hendrik Geldenhuys; Bernadette Pienaar; Sara Suliman; Phalkun Chheng; Sara M Debanne; Daniel F Hoft; W Henry Boom; Willem A Hanekom; John L Johnson
Journal:  Vaccine       Date:  2014-05-09       Impact factor: 3.641

3.  Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.

Authors:  Gerald K Chege; Wendy A Burgers; Helen Stutz; Ann E Meyers; Rosamund Chapman; Agano Kiravu; Rubina Bunjun; Enid G Shephard; William R Jacobs; Edward P Rybicki; Anna-Lise Williamson
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

4.  Differential effects of control and antigen-specific T cells on intracellular mycobacterial growth.

Authors:  S Worku; D F Hoft
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

5.  A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin.

Authors:  Angela M Minassian; Iman Satti; Ian D Poulton; Joel Meyer; Adrian V S Hill; Helen McShane
Journal:  J Infect Dis       Date:  2012-04-01       Impact factor: 7.759

6.  Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial.

Authors:  Daniel F Hoft; Azra Blazevic; Asmir Selimovic; Aldin Turan; Jan Tennant; Getahun Abate; John Fulkerson; Daniel E Zak; Robert Walker; Bruce McClain; Jerry Sadoff; Judy Scott; Barbara Shepherd; Jasur Ishmukhamedov; David A Hokey; Veerabadran Dheenadhayalan; Smitha Shankar; Lynn Amon; Garnet Navarro; Rebecca Podyminogin; Alan Aderem; Lew Barker; Michael Brennan; Robert S Wallis; Anne A Gershon; Michael D Gershon; Sharon Steinberg
Journal:  EBioMedicine       Date:  2016-04-19       Impact factor: 8.143

7.  Vaccines: past, present and future.

Authors:  Stanley A Plotkin
Journal:  Nat Med       Date:  2005-04       Impact factor: 53.440

8.  The Association of BCG Vaccination with Atopy and Asthma in Adults.

Authors:  Sung Soo Park; Eun Young Heo; Deog Kyeom Kim; Hee Soon Chung; Chang-Hoon Lee
Journal:  Int J Med Sci       Date:  2015-08-01       Impact factor: 3.738

9.  Maternal BCG scar is associated with increased infant proinflammatory immune responses.

Authors:  Patrice Akusa Mawa; Emily L Webb; Abdelali Filali-Mouhim; Gyaviira Nkurunungi; Rafick-Pierre Sekaly; Swaib Abubaker Lule; Sarah Prentice; Stephen Nash; Hazel M Dockrell; Alison M Elliott; Stephen Cose
Journal:  Vaccine       Date:  2016-11-30       Impact factor: 3.641

Review 10.  Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology.

Authors:  Ana F Rodrigues; Hugo R Soares; Miguel R Guerreiro; Paula M Alves; Ana S Coroadinha
Journal:  Biotechnol J       Date:  2015-07-24       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.